{"nctId":"NCT00127218","briefTitle":"High-Density Lipoprotein (HDL) Cholesterol Increased Plaque Stabilization in the Elderly","startDateStruct":{"date":"2003-09"},"conditions":["Atherosclerosis","Cardiovascular Disease"],"count":145,"armGroups":[{"label":"1","type":"EXPERIMENTAL","interventionNames":["Drug: any statin","Drug: niacin"]},{"label":"2","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: any statin","Drug: Placebo"]}],"interventions":[{"name":"any statin","otherNames":["fluvastatin (Lescol)","pravastatin (Pravachol)","simvastatin (Vytorin)","atorvastatin (Lipitor)","rosuvastatin (Crestor)"]},{"name":"niacin","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Aged 65 or older\n* Documented clinical cardiovascular or cerebrovascular disease due to atherosclerosis\n* Candidate for lipid lowering therapy; no contraindication to fluvastatin, niacin or aspirin therapy\n* Low-density lipoprotein (LDL) cholesterol below 150 mg/dl if untreated or below 125 mg/dl on statin monotherapy\n* Willing to discontinue present therapy if private physician agrees with enrollment\n* Eligible to undergo trans-esophageal magnetic resonance imaging (MRI); no contraindications to Gadolinium-DTPA, the contrast agent used\n* Willing to sign Informed Consent\n\nExclusion Criteria:\n\n* Ineligibility for MRI procedure due to pacemaker, metal implants, or other ferromagnetic devices\n* Claustrophobia\n* Previously documented esophageal disease which would preclude trans-esophageal MRI\n* LDL-C greater than 150 mg/dl off lipid lowering therapy or daily statin therapy requiring doses greater than 20 mg of atorvastatin, 20 mg of simvastatin, 80 mg of lovastatin, 80 mg of pravastatin, 80 mg of extended release fluvastatin, or 20 mg of rosuvastatin\n* Contraindication or allergy to statins or aspirin\n* Current use of or known intolerance or allergy to Niaspan (a long-acting niacin)\n* Allergy or intolerance to Gadolinium-DTPA (MRI contrast agent)\n* Liver or kidney failure defined clinically and by laboratory data\n* Mental, neurologic or social condition preventing understanding of the rationale, procedures, risks and potential benefits associated with the trial","healthyVolunteers":false,"sex":"ALL","minimumAge":"65 Years","stdAges":["OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Changes in Plaque Architecture and Composition Directly Measured by Magnetic Resonance Imaging (MRI) in the Aorta and Carotid Arteries","description":"The primary endpoint is Changes in plaque architecture and composition directly measured by magnetic resonance imaging (MRI) in the aorta and carotid arteries.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":".2"},{"groupId":"OG001","value":"5","spread":".2"}]}]}]},{"type":"SECONDARY","title":"Multiple Combined Events ( Cardiovascular and Cerebrovascular Events as Well as Myocardial Revascularization)","description":"Cerebrovascular events (newly diagnosed) such as Stroke and Myocardial revascularization (specifically coronary artery bypass grafting, percutaneous coronary interventions, carotid endarterectomy) were recorded","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":72},"commonTop":["Coronary Revascularization"]}}}